MGNX . . . It looks as though the most imminent catalyst is some data from MGD010. They may also partner this program late this year.I have a hard time understanding how important P1 efficacy data is when it consists of proxies like the following:
"MGD010 demonstrated linear pharmacokinetics and dose-dependent selective binding to B lymphocytes without persistent B-cell depletion. The data also showed: (1) a dose-dependent downregulation of B-cell receptor-induced signaling together with down-modulation of B-cell receptor expression among circulating memory and naïve B cells, (2) a decrease in expression of the costimulatory CD40 molecule and (3) a decrease in circulating immunoglobulin M levels, each consistent with the targeted action of MGD010. These data support the continued research and development of MGD010 in patients with autoimmune and inflammatory disorders."
and, from the CC: "We added one additional cohort where we gave MGD010 in combination with active vaccination, in this case to test antigen for Hepatitis A, and showed in a subset of those subjects in December, a profound reduction in induction of antibiotic specific responses."
Oh goody, P1 subset analysis! On an effect whose significance I don't even understand.
They said the right things about PK/PD and side effects, and from the above I can gather that it's hitting its targets as planned. But clinical relevance is fuzzy to me. You or Rick got any feel for this? I'm not sure if I could tell if the outcomes were really successful, though I'm sure the PR will say so unless there is abject failure.
TIA & Cheers, Tuck |
